Apply the power of OXISTAT® Lotion

OXISTAT® Lotion demonstrated greater efficacy in tinea pedis vs vehicle when dosed bid and qd1,2

Higher mycological cure rates with OXISTAT® Lotion in tinea pedis vs vehicle*1,2
(demonstrated 2 weeks post 4-week treatment)

Mycological cure1

  • No evidence (culture and potassium hydroxide [KOH] preparation) of the original pathogen
Mycological cure chart

Higher rates of treatment success with OXISTAT® Lotion in tinea pedis vs vehicle*1,2
(demonstrated 2 weeks post 4-week treatment)

Treatment success1

  • Global evaluation of 90% clinical improvement
  • Microbiological eradication
treatment success chart

In a clinical trial of 269 patients treated with OXISTAT® Lotion, the most common adverse events were burning and stinging (0.7% each) and pruritus, scaling, tingling, pain, and dyshidrotic eczema (0.4% each).1

* In a clinical trial of OXISTAT® Lotion involving 332 evaluable patients with clinically and microbiologically established tinea pedis.1

References: 1. OXISTAT® Cream, OXISTAT® Lotion [Prescribing Information, 2012]. Melville, NY: PharmaDerm, a division of Fougera Pharmaceuticals Inc. 2. Data on file, Fougera.

Discover the activity of OXISTAT lotion against fungi